Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 1999

View Archived Issues

Superoxide dimutase product may reduce asthma and neurodevelopmental deficits in neonates

Preclinical trials demonstrate neuroprotective activity of Vertex's neurophilin compounds

Phase I/II data presented for MEDI-507 in steroid-resistant GvHD

Licensing opportunity from NIH: antisense oligonucleotides for treating restenosis

Positive results announced for D-chiro-inositol in type II diabetes trial

ID Biomedical receives FDA clearance for Velogene Rapid MRSA Assay

FDA approves same-day, second-eye treatment with Sunrise LTK system

Abgenix and U.S. Army to cooperate on antibody-based defenses against filoviruses

StressGen begins second phase I safety trial of HspE7

Hyseq presents therapeutic candidate for reducing blood clotting

Klinge presents new compounds with both antitumor and immunosuppressive effects

SB discovers new class of compounds with high affinity for several 5-HT receptor subtypes

Novel antitumor agents from Rutgers act as topoisomerase poisons

New series from Novo Nordisk useful for pain, inflammation, NIDDM, etc.

Salix updates rifaximin clinical development as BID therapy

Double-strength formulation of Esterom to be tested in phase III

Potassium channel openers in development at Abbott for various medical conditions

Hoechst Marion Roussel files for new indication of Refludan in U.S. and E.U.

AltaRex proposes increase in enrollment in OvaRex MAb trial

International patent covers Kowa's new ACAT inhibitors

Gilead and NeXstar merger up for stockholder approval this month

New, physiologically balanced plasma volume expander now available in the U.S.

Pierre Fabre and Rega Institute embark on hantavirus vaccine project

Gidazepam exerts differential anxiolytic effects depending on individual reaction to stress

Proposed market formulation of Ro-64-0796 bioequivalent to other capsule and liquid formulations

Talinolol proves effective in addition to conventional therapy in CHF

CSAID from Italfarmaco prevents de novo formation of B1 receptors

Novel class III antiarrhythmic agent presented at scientific forum by Russian researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.